AstraZeneca
AZN | NYSE
$186.65
+$12.25 (+7.02%)
At close: Oct 30, 2026, 4:00 PM ET
$186.35
-$0.30 (-0.16%)
After-hours:
Oct 30, 2026, 7:33 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 58.74B | 54.07B | 45.81B | 44.35B | 37.42B | 26.62B |
Cost of Revenue | 10.63B | 10.21B | 8.27B | 12.39B | 12.44B | 5.3B |
Gross Profit | 48.11B | 43.87B | 37.54B | 31.96B | 24.98B | 21.32B |
Operating Income | 13.74B | 10B | 8.19B | 3.76B | 1.06B | 5.16B |
Interest Income | 360M | 345M | 301M | 81M | 43M | 83M |
Pretax Income | 12.4B | 8.69B | 6.9B | 2.5B | -265M | 3.92B |
Net Income | 10.26B | 7.04B | 5.96B | 3.29B | 112M | 3.2B |
Selling & General & Admin | 20.51B | 20.22B | 18.22B | 17.98B | 15.59B | 11.9B |
Research & Development | 14.23B | 13.58B | 10.94B | 9.76B | 9.74B | 5.99B |
Other Expenses | -381M | 56M | 193M | 457M | -1.4B | -1.73B |
Operating Expenses | 34.36B | 33.86B | 29.35B | 28.2B | 23.92B | 16.16B |
Interest Expense | 1.69B | 1.68B | 1.59B | 1.33B | 1.28B | 1.27B |
Selling & Marketing Expenses | 579M | 555M | 539M | 536M | 446M | 11.9B |
Cost & Expenses | 45B | 44.07B | 37.62B | 40.59B | 36.36B | 21.46B |
Income Tax Expense | 2.17B | 1.65B | 938M | -792M | -380M | 772M |
Shares Outstanding (Basic) | 775M | 775M | 781M | 774M | 709M | 656M |
Shares Outstanding (Diluted) | 781M | 781.5M | 781M | 780M | 713.5M | 656.5M |
EPS (Basic) | 13.20 | 9.08 | 7.62 | 4.24 | 0.16 | 4.88 |
EPS (Diluted) | 13.08 | 9 | 7.62 | 4.22 | 0.16 | 4.88 |
EBITDA | 19.83B | 15.44B | 13.42B | 9.09B | 5.11B | 8.08B |
EBIT | 14.1B | 10.37B | 8.49B | 3.83B | 1.01B | 5.19B |
Depreciation & Amortization | 5.73B | 5.07B | 4.93B | 5.25B | 4.1B | 2.9B |
Add to Watchlist
Select watchlists to add or remove AZN